Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from ResMed

ResMed Strengthens Its Out-Of-Hospital Software Solutions Position With Latest Acquisition - Read How

ResMed Inc (NYSE:RMD) has agreed to acquire privately-held MEDIFOX DAN, a Germany-based provider of out-of-hospital software solutions, from Hg, a software and services investor. MEDIFOX DAN's clinical, financial, and operational solutions are similar to ResMed's U.S. SaaS brands, MatrixCare and Brightree. MEDIFOX DAN's German customer base is complementary to the customers of ResMed's U.S.-based…

Analyst Ratings for ResMed

Analyst Ratings for ResMed

Analysts have provided the following ratings for ResMed (NYSE:RMD) within the last quarter:

Benzinga's Top Ratings Upgrades, Downgrades For June 6, 2022

Benzinga's Top Ratings Upgrades, Downgrades For June 6, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

If You Invested $100 In Resmed 5 Years Ago, Here's How Much You Would Have Today

ResMed (NYSE:RMD) has outperformed the market over the past 5 years by 12.16% on an annualized basis producing an average annual return of 23.39%. Currently, ResMed has a market capitalization of $30.35 billion.

ResMed Earnings Perspective: Return On Invested Capital

Pulled from Benzinga Pro data, ResMed (NYSE:RMD) posted Q3 earnings of $179.01 million, an increase from Q2 of 11.27%. Sales dropped to $864.50 million, a 3.39% decrease between quarters.

What 3 Analyst Ratings Have To Say About ResMed

Over the past 3 months, 3 analysts have published their opinion on ResMed (NYSE:RMD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

ResMed's Q3 Earnings Short Of Expectations, Profit Margins Contract

ResMed Inc's (NYSE:RMD) Q3 FY22 sales increased by 12% Y/Y (+14% on a constant currency basis) to $864.5 million, missing the consensus of $897 million. The revenue growth was driven by increased demand for sleep and respiratory care devices and an increased demand following an ongoing recall of rival Koninklijke Philips N.V. (NYSE:PHG) products. ResMed…

inkl

Read news from The Economist, FT, and more,
with one subscription

Earnings Outlook For ResMed

Earnings Outlook For ResMed

ResMed (NYSE:RMD) is set to give its latest quarterly earnings report on Thursday, 2022-04-28. Here's what investors need to know before the announcement. Analysts estimate that ResMed will report an earnings per share (EPS) of $1.42.

What 5 Analyst Ratings Have To Say About ResMed

What 5 Analyst Ratings Have To Say About ResMed

ResMed (NYSE:RMD) has observed the following analyst ratings within the last quarter:

3 Top S&P 500 Stock Market Gainers Today: Energy Dominates As Adobe Dives

3 Top S&P 500 Stock Market Gainers Today: Energy Dominates As Adobe Dives

Energy and commodity plays were top performers Wednesday. Adobe was the S&P 500's biggest loser.

Investors Business Daily

ResMed is our Growth Stock of the Week

ResMed is our Growth Stock of the Week

Over the last couple of decades, there has been an explosion in ‘lifestyle’ diseases like hypertension, obesity, and diabetes. Over time, these afflictions can start affecting patients’ respiratory and sleep patterns which can exacerbate health issues. Currently, about 5% of men in the US and 3% of women have respiratory…

5 Beaten-Down Medtech Stocks to Buy on the Dip

5 Beaten-Down Medtech Stocks to Buy on the Dip

Because record-high inflation and expected interest rate hikes are roiling the equity markets, it could be wise to buy MedTech stocks due to the industry's solid growth prospects and a near-inelastic demand for MedTech products with rising health awareness. So, we believe quality MedTech company stocks ResMed (RMD), Merit Medical…

Ominous Death Cross Forms On ResMed's Chart

Ominous Death Cross Forms On ResMed's Chart

If history is any guide, there may be trouble ahead for shares of ResMed (NYSE:RMD). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Expert Ratings For ResMed

Expert Ratings For ResMed

ResMed (NYSE:RMD) has observed the following analyst ratings within the last quarter:

Get all your
news in one place.

100’s of premium titles.
One news app.

ResMed's Return on Invested Capital Overview

According to Benzinga Pro, during Q2, ResMed (NYSE:RMD) earned $201.75 million, a 0.91% increase from the preceding quarter. ResMed's sales decreased to $894.87 million, a 1.01% change since Q1.

ResMed Q2 Earnings Highlights: Supply Chain Constraints, Unlimited Demand Due To Competitor Recall

ResMed Inc (NYSE: RMD) revealed a

Recap: ResMed Q2 Earnings

ResMed (NYSE:RMD) reported its Q2 earnings results on Thursday, January 27, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Earnings Preview: ResMed

ResMed (NYSE:RMD) is set to give its latest quarterly earnings report on Thursday, 2022-01-27. Here's what investors need to know before the announcement. Analysts estimate that ResMed will likely report an Earnings Per Share (EPS) of $1.52.

Get all your
news in one place.

100’s of premium titles.
One news app.

Is ResMed a Buy Under $250?

Currently trading at less than $250, ResMed Inc. (RMD) exhibited solid fundamental performance in its last reported quarter based on its strong sales growth across its product portfolio. So, given favorable analysts' sentiments about the stock and the company’s strong profitability, is it worth betting on the stock now? Read…

Organisations

American Express

CrowdStrike Holdings

Lululemon Athletica

BristolMyers Squibb

Spotify Technology

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

303,060 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play